North American prostate cancer diagnostics and therapeutics market is expected to grow at a CAGR of 10.4% during the forecast period. The major factors for the growth of the market include the high prevalence of prostate cancer in the region which raises the demand for efficient diagnostics and therapies for the treatment of cancer. As per World Health Organization, in the North America, prostate cancer is the most prevalent cancer among men. Around 234,000 new cases of prostate cancer has been registered in 2018 in the region. Additionally, in 2018, around 18.5% of the total cases of cancer are related to prostate cancer in the US. Moreover, the adoption of innovative technologies for the diagnosis of prostate cancer such as biomarkers and the adoption of personalized medicine for treatment is expected to fuel the market.